Discovery and development of anticancer agents from marine sponges: Perspectives based on a chemistry-experimental therapeutics collaborative program

Journal of Experimental Therapeutics and Oncology

Volumn 10, Issue 2, 2012, Pages 119-134

  Valeriote, Frederick A ^a   Tenney, Karen ^b   Media, Joseph ^a   Pietraszkiewicz, Halina ^a   Edelstein, Matthew ^a   Johnson, Tyler A ^b   Amagata, Taro ^b   Crews, Phillip ^b  

^a Josephine Ford Cancer Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticancer drugs; Marine sponges; Natural products

Indexed keywords

10 BROMOFASCAPLYSIN; 5 METHOXYNEOAMPHIMEDINE; ALPKINIDINE; ALPKINIDINE C; ANTINEOPLASTIC AGENT; BENGAMIDE A; BENGAMIDE B; BENGAMIDE E; BENGAMIDE F; BENGAMIDE M; BENGAMIDE O; BISTHEONELLIDE A; CYCLOLITHISTIDE A; ETHYLDIDEHYDROPLAKORTIDE Z; ETHYLPLAKORTIDE Z; FASCAPLYSIN; FASCAPLYSIN A; HALICHONDRIA MELANADOCIA EXTRACT; LAF 389; LEUCETTA EXTRACT; MAKALUVAMINE C; MAKALUVAMINE H; NATURAL PRODUCT; NEOAMPHIMEDINE; PLAKINIDINE A; PSYMBERIN; THEOPAPUAMIDE; TOPSENTIA CEYLONENSIS EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CARDIOVASCULAR DISEASE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DISK DIFFUSION; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TUMOR LEVEL; FASCAPLYSINOPSIS; HUMAN; HUMAN CELL; IC 50; IRCINIA; JASPIS CORIACEA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PLAKORTIS; PRIORITY JOURNAL; PSAMMOCINIA; REVIEW; SOLID TUMOR; SPONGE (PORIFERA); XESTOSPONGIA; ZYZZYA;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; COLONY-FORMING UNITS ASSAY; DRUGS, INVESTIGATIONAL; HUMANS; MICE; MICE, SCID; MOLECULAR STRUCTURE; PORIFERA; THERAPEUTICS; TUMOR CELLS, CULTURED;

EID: 84873402162     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477, 2007.
2. Cragg GM, Newman DJ. Developments and future trends in anticancer natural products drug discovery. In: Cragg GM, Kingston DGI, Newman DJ, eds. Anticancer agents from natural products. Boca Raton: CRC Press 699-727, 2012.
3. Simmons TL, Gerwick WH. Anticancer drugs of marine origin. In: Walsh PJ, Smith SL, Fleming LE, Solo-Gabriele HM, Gerwick WH, eds. Oceans and human health. Risks and Remedies from the Seas. Boston: Elsevier 431-452, 2008.
4. Schmitz FJ. Cytotoxic compounds from sponges and associated microfauna. In. Van Soest RWM, Van Kempen TMJ, Braekman J-C. eds, Sponges in time and space. Biology, chemistry and paleontology. Rotterdam: AA Balkema 485-496, 1994.
5. Munro MH, Blunt JW, Dumdei EJ, Hickford SJ, Lill RE, Li S, Battershill CN Duckworth AR. The discovery and development of marine compounds with pharmaceutical potential. J Biotechnol 70: 15-25, 1999.
6. Mayer AMS, Gustafson KR. Marine pharmacology in 2001-2: Antitumor and cytotoxic compounds. Eur J Cancer 40: 2676-2704, 2004.
7. Mayer AMS, Gustafson ER. Marine pharmacology in 2003-2004: Anti-tumor and cytotoxic compounds. Eur J Cancer 42: 2241-2270, 2006.
8. Sashidhara K, White K, Crews P. A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products. J Nat Prod 72: 583-603, 2009.
9. Subramanian B, Nakeff A, Tenney K, Crews P, Gunatilaka L, Valeriote F. A new paradigm for the development of anticancer agents from natural products. J Exp Ther Oncol 5: 195-204, 2006.
10. Valeriote F, Grieshaber CK, Media J, Pietraszkiewicz H, Hoffmann J, Pan M, McLaughlin S. Discovery and development of anticancer agents from plants. J Expl Therap Oncol 2: 228-236, 2002.
11. Corbett TH, Valeriote FA, Baker LH. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5: 3-20, 1987.
12. Corbett TH, Valeriote FA. Rodent models in experimental chemotherapy. In: Kallman, RF, ed. Rodent tumor models in experimental cancer therapy. New York: Pergamon Press 233-247, 1987.
13. Corbett TH, Bissery M-C, Wozniak A, Plowman J, Polin L, Tapazoglou E, Dieckman J, Valeriote, F. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 4: 207-220, 1986.
14. Mucci-LoRusso P, Polin L, Biernat LA, Valeriote FA, Corbett TH. Activity of datelliptium chloride (NSC 311152; SR95156A) against solid tumors of mice. Invest New Drugs 8: 253-261, 1990.
15. Corbett T, Valeriote F, Polin L, et al. Discovery of solid tumor active agents using a soft-agar-colony formation disk-diffusionassay. In:, Valeriote FA, Corbett TH, Baker LH, eds. Cytotoxic anticancer drugs: Models and concepts for drug discovery and development. Norwell: Kluwer Academic Publishers 35-87, 1992.
16. Trimurtulu G, Ohtani I, Patterson GML, Moore RE, Corbett TH, Valeriote FA, Demchik L. Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. Strain GSV224. J Am Chem Soc 116: 4729-4737, 1994.
17. Valeriote F, Moore RE, Patterson GML, Paul VJ, Scheuer P, Corbett T. Discovery of natural products from microalgae and marine organisms. In: Valeriote FA, Corbett TH, Baker LH, eds. Anticancer drug discovery and development: Natural products and new molecular models. Boston: Kluwer Academic Publishers 1-25, 1994.
18. Valeriote F, Corbett T, LoRusso P, Moore R, Scheuer P, Paterson G, Paul V, Grindey G, Bonjouklian R, Pearce H. Discovery of anticancer agents from natural products. Int J Pharmacognosy 33(Supp): 59-66, 1995.
19. Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lisow L. Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacognosy, 33(Supp): 102-122, 1995.
20. Polin L, Valeriote F, White K, Jones J, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Peltier N, Golakoti T, Patterson G, Moore R,Corbett TH. Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs 15: 99-108, 1997.
21. Thale Z, Johnson T, Tenney K, Wenzel PJ, Lobkovsky E, Clardy J, Media J, Pietraszkiewicz H, Valeriote FA, Crews P. Structures and cytotoxic properties of sponge-derived bisannulated acridines. J Org Chem 67: 9384-9391, 2002.
22. Segraves NL, Lopez S, Johnson TA, Said SA, Fu X, Schmitz FJ, Pietraszkiewicz H, Valeriote FA, Crews P. Structure and cytotoxicities of fascaplysin and related alkaloids from two marine phyla-Fascaplysinopsis sponges and Didemnum tunicates. Tetrahedron Lett 44: 3471-3475, 2003.
23. Cichewicz RH, Valeriote FA, Crews P. Psymberin, a potent sponge-derived cytotoxin from Psammocinia distantly related to the pederin family. Org Lett 6: 1951-1952, 2004.
24. Ralifo P, Crews P. A new structural theme in the imidazolecontaining alkaloids from a calcareous Leucetta sponge. J Org Chem 69: 9025-9029, 2004.
25. Crews P, Rodriguez J, Jaspars M (eds) Organic strtucture analysis. 2nd ed. New York: Oxford University Press, 2010.
26. Watts KR, Morinaka BI, Amagata T, Robinson S, Tenney K, Bray WM, Gassner NC, Lokey RS, Media J, Valeriote FA, Crews P. Biostructural features of additional jasplakinolide (jaspamide) analogues. J Nat Prod 74: 341-351, 2011.
27. Valeriote F, Corbett T, LoRusso P, Moore RE, et al. Discovery of anticancer agents from natural products. Int J Pharmacognosy 33, Supplement: 59-66, 1995.
28. Roll DM, Ireland CM, Lu HSM, Clardy J. Fascaplysin, an unusual pigment from the marine sponge Fascaplysinopsis sp. J Org Chem 53: 3276-3278, 1988.
29. Jimenez C, Quinoa E, Adamczeski M, Hunter L, Crews P. Novel sponge-derived amino acids. 12. Tryptophan-derived pigments and accompanying sesterterpenes from fascaplysinopsis reticulata. J Org Chem 56: 3403-3410, 1991.
30. Segraves NL, Robinson SJ, Garcia D, Said SA, Fu X, Schmitz FJ, Pietraszkiewicz H, Valeriote FA, Crews P. Comparison of fascaplysin and related alkaloids: A study of structures, cytotoxicities, and sources. J Nat Prod 67: 783-792, 2004.
31. Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S, Fretz H, Chaudhuri B. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem Biophys Res Comm 275: 877-884, 2000.
32. Hormann A, Chaudhuri B, Fretz H. DNA binding properties of the marine sponge pigment fascaplysin. Bioorg Med Chem 9: 917-921, 2001.
33. Quinoa E, Adamczeski M, Crews P, Bakus G. Bengamides, heterocyclic anthelminthics from a Jaspidae marine sponge. J Org Chem 51: 4494-4497, 1986.
34. Adamczeski M, Quinoa E, Crews P. Novel sponge-derived amino acids. 5. Structures, stereochemistry, and synthesis of several new heterocycles. J Am Chem Soc 111: 647-654, 1989.
35. Groweiss A, Newcomer JJ, O'Keefe BR, Blackman A, Boyd MR. Cytotoxic metabolites from an Australian collection of the sponge Jaspis species. J Nat Prod 62: 1691-1693, 1999.
36. Thale Z, Kinder FR, Bair KW, Bontempo J, Czuchta AM, Versace RW, Phillips PE, Sanders ML, Wattanasin S, Crews, P. Bengamides revisited: New structures and antitumor studies. J Org Chem 66: 1733-1741, 2001.
37. Kinder FR Jr, Versace RW, Bair KW, Bontemp JM, Cesarz D, Chen S, Crews P, Czuchta AM, Jagoe CT, Mou Y, Nemzek R, Phillips PE, Tran LD, Wang RM, Weltchek S, Zabludoff S. Synthesis and antitumor activity of ester-modified analogues of bengamide B. J Med Chem 44: 3692-3699, 2001.
38. Dumez H, Gall H, Capdeville R, Dutreix C, van Oosterom AT, Giaccone G. A phase I and pharmacokinetic study of LAF389 administered to patients with advancer cancer. Anti-Cancer Drugs 18: 219-225, 2007.
39. Hu X, Dang Y, Tenney K, Crews P, Tsai CW, Sixt KM, Cole PA Liu JO. Regulation of c-Src nonreceptor tyrosine kinase activity by bengamide A through inhibition of methionine aminopeptidases. Chem Biol 14: 764-774, 2007.
40. Schmitz FJ, Agarwal SK, Gunasedera SP, Schmidt PG, Shoolery JN. Amphimedine, new aromatic alkaloid from a Pacific sponge Amphimedon sp. Carbon connectivity determination from natural abundance carbon-13-carbon-13 coupling constants. J Am Chem Soc 105: 4835-4836, 1983.
41. De Guzman FS, Carte B, Troupe N, Faulkner DJ, Harper MK, Concepcion GP, Mangalindan GC, Matsumoto SS, Barrows LR, Ireland CM. Neoamphimedine: A new pyridoacridine topoisomerase II inhibitor which catenates DNA. J Org Chem 64: 1400-1402, 1999.
42. Marshall KM, Matsumoto SS, Holden JA, Concepcion GP, Tasdemir D, Ireland CM, Barrows LR. The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine. Biochem Pharmacol 66: 447-458, 2003.
43. Marshall KM, Barrows LR. Biological activities of pyridoacridines. Nat Prod Rev 21: 731-751, 2004.
44. Radisky DC, Radisky ES, Barrows LR, Copp BR, Kramer RA, Ireland CM. Novel cytotoxic topoisomerase II inhibiting prrroloiminoquinones from Fijian sponges of the genus Zyzzya. J Am Chem Soc 115: 1632-1638, 1993.
45. Schmidt EW, Harper MK, Faulkner DJ. Makaluvamines H-M and damirone C from the Pohnpeian sponge Zyzzya fulginosa. J Nat Prod 58: 1861-1867, 1995.
46. Dijoux M-G, Schnabel PC, Hallock YF, Boswell JL, Johnson TR, Wilson JA, Ireland CM, van Soest R, Boyd M, Barrows LR, Cardellina JHII. Antitumor activity and distribution of pyrroloiminoquinones in the sponge genus Zyzzya. Bioorg Med Chem 13: 6035-6044, 2005.
47. Ding Q, Chichak K, Lown JW. Pyrroloquinoline and pyridoacridine alkaloids from marine sources. Curr Med Chem 6: 1-27, 1999.
48. Matsumoto SS, Haughey HM, Schmehl DM, Venables DA, Ireland CM, Holden JA, Barrows LR. Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction. Anticancer Drugs 10: 39-45, 1999.
49. Chen T, Xu Y, Guo H, Liu Y, Hu P, Li X, Ge S, Velu S, Nadkarni DH, Wang W, Zhang R, Wang H. Experimental therapy of ovarian cancer with synthetic makaluvamine analog: In vitro and in vivo anticancer activity and molecular mechanism of action. PlosOne 6: 1-10, 2011.
50. Marshall KM, Barrows LR. Biological activities of pyridoacridines. Nat Prod Rep 21: 731-751, 2004.
51. Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugeson S, Zhang R. In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15: 3511-3518, 2009.
52. Pettit G R, Xu J-P, Chapuis J-C, Pettit RK, Tackett LP, Doubek DL, Hooper JNA, Schmidt JM. Antineoplastic agents. 520. Isolation and structure of irciniastatins A and B from the Indo-Pacific marine sponge Ircinia ramosa. J Med Chem 47: 1149-1152, 2004.
53. Huang XH, Shao N, Huryk R, Palani A, Aslanian R, Seidel-Dugan C. The discovery of potent antitumor agent C11-deoxypsymberin/irciniastatin A: Total synthesis and biology of advanced psymberin analogs. Org Letters 11: 867-870,2009.
54. Robinson SJ, Tenney K, Yee DF, Martinez L, Media JE, Valeriote FA, vanSoest RWM, Crews P. Probing the bioactive constituents from chemotypes of the sponge Psammocinia aff. bulbosa. J Nat Prod 70: 1002-1009, 2007.
55. Jiang X, Williams N, DeBrabander JK. Synthesis of psymberin analogues: Probing a functional correlation with the pederin/ mycalamide family of natural products. Org Lett 9: 227-230, 2007.
56. Harrison B, Crews P. Cyclic polyketide peroxides and acyclic diol analogues from the sponge Plakortis lita. J Nat Prod 61: 1033-1037, 1998.
57. Inman WD, Oneill-Johnson M, Crews P. Novel marine sponge alkaloids. 1. Plakinidine A and B, anthelmintic active alkaloids from a Plakortis sponge. J Amer Chem Soc 112: 1-4, 1990.
58. Ralifo P, Sanchez L, Gassner NC, Tenney K, Lokey RS, Holman TR, Valeriote FA, Crews P. Pyrroloacridine alkaloiods from Plakortis quasiamphiaster: Structure and bioactivity. J Nat Prod 70: 95-99, 2007.
59. Dunbar DC, Rimoldi JM, Clarke M, Hamman MT. Anticryptococcal and nitric oxide synthase inhibitory imidazole alkaloids from the calcareous sponge Leucetta cf chagosensis. Tetrahedron 56: 8795-8798, 2000.
60. Crews P, Clark DP, Kenney K. Variations in alkaloids among Indo-Pacific Leucetta sponges. J Nat Prod 66: 177-182, 2003.
61. White KN, Amagata T, Oliver AG, Tenney K, Wenzel P, Crews P. Structure revision of spiroleucettadine, a sponge alkaloid with a bicyclic core meager in H-atoms. J Org Chem 73: 8719-8722, 2008.
62. Kong F, Faulkner DJ. Leucettamines A and B, two antimicrobial lipids from the calcareous sponge Leucetta microraphis. J Org Chem 58: 970-971, 1993.
63. Simmons TL, Andrianasolo E, McPhail K, Platt P, Gerwick WL. Marine natural products as anticancer drugs. Mol Cancer Ther 4: 333-342, 2005.
64. Schmitz FJ, Hollenbeak KH, Campbell DC. Marine natural products: Halitoxin, toxic complex of several marine sponges of the genus Haliclona. J Org Chem 43: 3916-3922, 1978.
65. Randazzo A, Debitus C, Gomez-Paloma L. Haliclamide, a novel cyclic metabolite from the Vanuatu marine sponge Haliclona sp. Tetrahedron 57: 4443-4446, 2001.
66. Rashid MA, Gustafson KR, Boyd MR. A new isoquinoline alkaloid from the marine sponge Haliclona species. J Nat Prod 64: 1249-1250, 2001.
67. Luo X, Li F, Shinde P, Hong J, Lee L-O, Im K, Jung J. 26, 27-cyclosterols and other polyoxygenated sterols from a marine sponge topsentia sp. J Nat Prod 69: 1760-1768, 2006.
68. Wegerski C, Hammond J, Tenney K, Matainaho T, Crews P. A serendipitous discovery of isomotuporin-containing sponge populations of Theonella swinhoei. J Nat Prod 70: 89-94, 2007.
69. Clark DP, Carroll J, Naylor S, Crews P. An antifungal cyclodepsipeptide, cyclolithistide A, from sponge Theonella swinhoei. J Org Chem 63, 8757-8764, 1998.
70. Sakai R, Higa T, Kashman Y. Misakinolide-A, an antitumor macrolide from the marine sponge Theonella sp. Chem Lett 1499-1502, 1986.
71. Oda T, Xu J, Fujita A, Mochizuki M, Namikoshi M. Effects of bistheonellide A, an actin-polymerization inhibitor, on Chinese hamster V79 cells and on IL-8 production in PMA-stimulated HL-60 cells. Marine Drugs 4: 22-27, 2006.
72. Ratnayake AS, Bugni TS, Feng X, Harper MK, Skalicky JJ, Mohammed KA, Andjelic CD, Barrows LR, Ireland CM. Theopapuamide: A cyclic depsipeptide from a Papua New Guinea Lithistid sponge Theonella swinhoei. J Nat Prod 69: 1582-1586, 2008.
73. Petrichtcheva NV, Duque C, Duenas A, Zea S, Hara N, Fujimoto Y. New nitrogenous eudesmane-type compounds isolated from the Caribbean sponge Axinyssa ambrosia. J Nat Prod 65: 851-855, 2002.
74. Zhong HM, Sohn J-H, Rawal VH. Studies toward the asymmetric synthesis of the right part of the mycalamides. J Org Chem 72: 386-397, 2007.
75. Newman DJ, Cragg GM. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67: 1216-1238, 2004.
76. Sipkema D, Franssen MCR, Osinga R, Tramper J, Wijffels RH. Marine sponges as pharmacy. Marine Biotech 7: 142-162, 2005.